ALDX vs SGP
ALDX: Aldeyra is a clinical-stage biotech pursuing FDA approval of reproxalap, an aldehyde dehydrogenase activator for ophthalmologic inflammation, dependent on addressing regulatory feedback and securing capital for development and commercialization. SGP: Spyglass Pharma is a clinical-stage biotech developing an innovative sustained-release drug delivery platform to improve patient outcomes in cataract surgery.
Side-by-side fundamentals
| Metric | ALDX | SGP | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $1.59 | $20.82 | |
| Market cap as of 2026-07-30 | $96M | $696M | |
| ROE as of 2026-07-30 | -57.3% | -75.4% | ALDX higher |
| ROA as of 2026-07-30 | -36.3% | -68.8% | ALDX higher |
| Debt / equity as of 2026-07-30 | 0.36 | 0.00 | SGP lower |
| Beta as of 2026-07-30 | 1.22 | 0.91 | |
| 1-year return as of 2026-07-27 close | -69.3% | n/a |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.